Time Passages: Bruce Goldsmith out at Jim Wilson's gene therapy biotech; Flagship reveals Michael Severino’s CEO gig
→ When Passage Bio readjusted its pipeline priorities, pruned its workforce by 13% and saw its R&D chief Eliseo Salinas walk out in March, it would be natural to assume that this confluence of events could lead to more imminent changes. This week, CEO Bruce Goldsmith followed Salinas and board member Liam Ratcliffe out the door.
Passage Bio and Goldsmith both felt it was in their best interests to move on as the Jim Wilson biotech shifts its focus to GM1 gangliosidosis, Krabbe disease and frontotemporal dementia. General counsel and corporate secretary Edgar “Chip” Cale has been named interim chief as the search gets underway for Goldsmith’s replacement, having leaped to Passage Bio in 2019 after a 21-year career at GSK that concluded as SVP, legal corporate projects. Goldsmith left Deerfield to succeed co-founder Stephen Squinto as Passage Bio’s CEO in early 2020.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.